Il y a eu 50 transactions d'initiés récentes enregistrées pour Arcturus Therapeutics Holdings Inc. (ARCT), dont 29 achats et 19 ventes. Le total des achats d'initiés s'élève à $24.34M et le total des ventes d'initiés à $5.5M.
Les initiés notables ayant une activité récente comprennent Payne Joseph E, Chivukula Pad, Kurata Lance. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — ARCT
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2025-12-17 |
Payne Joseph E |
President and CEO |
Attribution de RSU |
175,000 |
$6.52 |
$1.14M |
175,000 |
| 2025-12-17 |
Chivukula Pad |
Chief Scientific Officer & COO |
Attribution de RSU |
54,000 |
$6.52 |
$352.08K |
54,000 |
| 2025-12-17 |
Kurata Lance |
Chief Legal Officer |
Attribution de RSU |
54,000 |
$6.52 |
$352.08K |
54,000 |
| 2025-12-17 |
Roberts Joseph |
Controller |
Attribution de RSU |
10,000 |
$6.52 |
$65.2K |
10,000 |
| 2025-12-12 |
Roberts Joseph |
Controller |
Inconnu |
7,500 |
$28.88 |
$216.6K |
- |
| 2025-08-15 |
Sassine Andy |
Chief Financial Officer |
Vente Informative |
1,238 |
$16.56 |
$20.5K |
221,764 |
| 2025-08-15 |
Sassine Andy |
Chief Financial Officer |
Achat Informatif |
1,238 |
$16.56 |
$20.5K |
221,764 |
| 2025-06-09 |
Farrell Peter C |
Director |
Attribution de RSU |
15,000 |
$12.54 |
$188.1K |
15,000 |
| 2025-06-09 |
Barlow James F |
Director |
Attribution de RSU |
15,000 |
$12.54 |
$188.1K |
15,000 |
| 2025-06-09 |
Holmes Edward W |
Director |
Attribution de RSU |
15,000 |
$12.54 |
$188.1K |
15,000 |
| 2025-06-09 |
Marquet Magda |
Director |
Attribution de RSU |
15,000 |
$12.54 |
$188.1K |
15,000 |
| 2025-06-09 |
Slaoui Moncef |
Director |
Attribution de RSU |
15,000 |
$12.54 |
$188.1K |
15,000 |
| 2025-06-09 |
Markels John |
Director |
Attribution de RSU |
15,000 |
$12.54 |
$188.1K |
15,000 |
| 2025-06-09 |
Marantz Jing L. |
Director |
Attribution de RSU |
15,000 |
$12.54 |
$188.1K |
15,000 |
| 2024-12-16 |
Sassine Andy |
Chief Financial Officer |
Attribution de RSU |
60,000 |
$16.24 |
$974.4K |
60,000 |
| 2024-12-16 |
Payne Joseph E |
President and CEO |
Attribution de RSU |
196,000 |
$16.24 |
$3.18M |
196,000 |
| 2024-12-16 |
Chivukula Pad |
Chief Scientific Officer & COO |
Attribution de RSU |
60,000 |
$16.24 |
$974.4K |
60,000 |
| 2024-12-16 |
Kurata Lance |
Chief Legal Officer |
Attribution de RSU |
60,000 |
$16.24 |
$974.4K |
60,000 |
| 2024-10-15 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
12,000 |
$20.76 |
$249.12K |
435,334 |
| 2024-06-19 |
Slaoui Moncef |
Director |
Inconnu |
- |
- |
- |
- |
| 2024-06-19 |
Slaoui Moncef |
Director |
Attribution de RSU |
14,794 |
$25.96 |
$384.05K |
14,794 |
| 2024-06-14 |
Farrell Peter C |
Director |
Exercice d'Options (Vente) |
3,131 |
- |
- |
- |
| 2024-06-14 |
Barlow James F |
Director |
Exercice d'Options (Vente) |
3,131 |
- |
- |
- |
| 2024-06-14 |
Holmes Edward W |
Director |
Exercice d'Options (Vente) |
3,131 |
- |
- |
- |
| 2024-06-14 |
Marquet Magda |
Director |
Exercice d'Options (Vente) |
3,131 |
- |
- |
- |
| 2024-06-14 |
Markels John |
Director |
Exercice d'Options (Vente) |
3,131 |
- |
- |
- |
| 2024-06-14 |
Marantz Jing L. |
Director |
Exercice d'Options (Vente) |
3,131 |
- |
- |
- |
| 2024-06-12 |
Sassine Andy |
Chief Financial Officer |
Vente Informative |
50,000 |
$32.03 |
$1.6M |
220,526 |
| 2024-06-05 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
114 |
$45.00 |
$5.13K |
447,334 |
| 2024-06-03 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
26,000 |
$40.01 |
$1.04M |
447,448 |
| 2024-03-25 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
17,435 |
$35.02 |
$610.57K |
473,448 |
| 2024-03-19 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
8,565 |
$35.01 |
$299.84K |
490,883 |
| 2023-12-15 |
Sassine Andy |
Chief Financial Officer |
Attribution de RSU |
75,000 |
$28.88 |
$2.17M |
75,000 |
| 2023-12-15 |
Payne Joseph E |
President and CEO |
Attribution de RSU |
200,000 |
$28.88 |
$5.78M |
200,000 |
| 2023-12-15 |
Chivukula Pad |
Chief Scientific Officer & COO |
Attribution de RSU |
125,000 |
$28.88 |
$3.61M |
125,000 |
| 2023-12-15 |
Kummerfeld Keith C |
See Remarks |
Attribution de RSU |
30,000 |
$28.88 |
$866.4K |
30,000 |
| 2023-12-15 |
Kurata Lance |
Chief Legal Officer |
Attribution de RSU |
75,000 |
$28.88 |
$2.17M |
75,000 |
| 2023-11-01 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
5,000 |
$18.72 |
$93.6K |
499,448 |
| 2023-10-02 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
5,000 |
$25.61 |
$128.06K |
504,448 |
| 2023-09-01 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
5,000 |
$31.45 |
$157.26K |
509,448 |
| 2023-08-15 |
Sassine Andy |
Chief Financial Officer |
Attribution de RSU |
1,223 |
$17.37 |
$21.25K |
270,526 |
| 2023-08-01 |
Farrell Peter C |
Director |
Attribution de RSU |
3,131 |
- |
- |
3,131 |
| 2023-08-01 |
Barlow James F |
Director |
Attribution de RSU |
3,131 |
- |
- |
3,131 |
| 2023-08-01 |
Holmes Edward W |
Director |
Attribution de RSU |
3,131 |
- |
- |
3,131 |
| 2023-08-01 |
Marquet Magda |
Director |
Attribution de RSU |
3,131 |
- |
- |
3,131 |
| 2023-08-01 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
5,000 |
$34.91 |
$174.55K |
514,448 |
| 2023-08-01 |
Markels John |
Director |
Attribution de RSU |
3,131 |
- |
- |
3,131 |
| 2023-08-01 |
Marantz Jing L. |
Director |
Attribution de RSU |
3,131 |
- |
- |
3,131 |
| 2023-07-14 |
Chivukula Pad |
Chief Scientific Officer & COO |
Vente Informative |
25,000 |
$35.01 |
$875.25K |
519,448 |
| 2023-07-14 |
Kummerfeld Keith C |
See Remarks |
Vente Informative |
6,968 |
$35.00 |
$243.88K |
950 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
